Literature DB >> 7747147

Mortality from cancer in patients with rheumatoid arthritis.

R Myllykangas-Luosujärvi1, K Aho, H Isomäki.   

Abstract

Data in nationwide Finnish registers were used to study the relationship between rheumatoid arthritis (RA) and site-specific cancers as a cause of death. The study included in all 1,666 subjects who had died in 1989 and who were entitled, under the nationwide sickness insurance scheme, to specially reimbursed medication because of RA. There were 277 deaths from malignancies. The proportion of such deaths in relation to all deaths declined with the duration of RA (p < 0.05). There was an excess of hematopoietic malignancies, particularly in males (p < 0.05). Deaths due to these malignancies, in relation to all cancer deaths, accumulated in long-lasting RA (p < 0.05). This suggests that hematopoietic malignancies arise as a complication of either RA or its treatment and to some degree argues against the notion of a shared etiological agent for these diseases.

Entities:  

Mesh:

Year:  1995        PMID: 7747147     DOI: 10.3109/03009749509099288

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

2.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

3.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; L Brandt; E Baecklund; L Bertilsson; N Feltelius; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog
Journal:  Ann Rheum Dis       Date:  2005-04-13       Impact factor: 19.103

4.  Does social disadvantage contribute to the excess mortality in rheumatoid arthritis patients?

Authors:  N Maiden; H A Capell; R Madhok; R Hampson; E A Thomson
Journal:  Ann Rheum Dis       Date:  1999-09       Impact factor: 19.103

Review 5.  Safety of tumour necrosis factor-alpha antagonists.

Authors:  Dinesh Khanna; Maureen McMahon; Daniel E Furst
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

6.  Risk factors for tumor occurrence in patients with myasthenia gravis.

Authors:  Antonietta Citterio; Ettore Beghi; Andrea Millul; Amelia Evoli; Renato Mantegazza; Carlo Antozzi; Fulvio Baggi; Ferdinando Cornelio; Luca Durelli; Marinella Clerico; Giovanni Piccolo; Vittorio Cosi
Journal:  J Neurol       Date:  2009-03-29       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.